The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).

Inclusion Criteria:

• Age ≥18 years old
• Has a diagnosis of advanced RCC
• Has received at least one prior VEGF-targeted therapy
• For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
• No previous exposure to cabozantinib prior to inclusion
• Not concurrently involved in an interventional study
• Consents to participate in this noninterventional study

Exclusion Criteria:

• There are no exclusion criteria for this study.

Subjects with advanced RCC following prior VEGF-targeted therapy in real life settings.